{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ROS1+Gene+Rearrangement", "query": { "condition": "ROS1 Gene Rearrangement" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ROS1+Gene+Rearrangement&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T03:06:34.253Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Savolitinib", "type": "DRUG" }, { "name": "Gefitinib", "type": "DRUG" }, { "name": "Necitumumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 247, "start_date": "2019-06-25", "completion_date": "2025-05-06", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03944772" }, { "nct_id": "NCT02321501", "title": "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Positive", "Locally Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "ROS1 Gene Rearrangement", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Ceritinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-06-22", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02321501" }, { "nct_id": "NCT05681780", "title": "Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Recurrent Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Tumor-infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tumor-infiltrating Lymphocyte Therapy", "type": "OTHER" }, { "name": "Interleukin-2 (IL2)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-03-10", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05681780" }, { "nct_id": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "Oral repotrectinib (TPX-0005)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 500, "start_date": "2017-03-07", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 49, "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 36 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093116" }, { "nct_id": "NCT04005144", "title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALK Gene Rearrangement", "Lung Non-Small Cell Carcinoma", "Progressive Disease", "ROS1 Gene Rearrangement", "Stage IIIB Lung Cancer", "Stage IIIC Lung Cancer", "Stage IV Lung Cancer", "Stage IVA Lung Cancer", "Stage IVB Lung Cancer" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Brigatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-02-25", "completion_date": "2022-10-01", "has_results": false, "last_update_posted_date": "2022-10-17", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005144" }, { "nct_id": "NCT05828303", "title": "A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "TPX-0005", "type": "DRUG" }, { "name": "Metformin Hydrochloride", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin Calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-11-15", "completion_date": "2025-11-30", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 2, "location_summary": "Canton, Ohio", "locations": [ { "city": "Canton", "state": "Ohio" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828303" }, { "nct_id": "NCT05118789", "title": "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Zidesamtinib (NVL-520)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 359, "start_date": "2022-01-04", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 20, "location_summary": "Orange, California • Palo Alto, California • Sacramento, California + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05118789" }, { "nct_id": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Cholangiocarcinoma", "Colorectal Cancer", "Head and Neck Neoplasms", "Lymphoma, Large-Cell, Anaplastic", "Melanoma", "Neuroendocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Papillary Thyroid Cancer", "Primary Brain Tumors", "Renal Cell Carcinoma", "Sarcomas", "Salivary Gland Cancers", "Adult Solid Tumor" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2015-11-19", "completion_date": "2026-05-14", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568267" }, { "nct_id": "NCT00585195", "title": "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer ALK-positive", "Non-Small Cell Lung Cancer c-Met Dependent", "Non-Small Cell Lung Cancer ROS Marker Positive", "Systemic Anaplastic Large-Cell Lymphoma", "Advanced Malignancies Except Leukemia" ], "interventions": [ { "name": "PF-02341066", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 596, "start_date": "2006-04-19", "completion_date": "2022-01-19", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 24, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00585195" }, { "nct_id": "NCT02650401", "title": "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "CNS Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 69, "start_date": "2016-05-03", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-05-22T03:06:34.253Z", "location_count": 15, "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650401" } ] }